Shang, Runze
Song, Xinhua
Wang, Pan
Zhou, Yi
Lu, Xinjun
Wang, Jingxiao
Xu, Meng
Chen, Xinyan
Utpatel, Kirsten
Che, Li
Liang, Binyong
Cigliano, Antonio
Evert, Matthias
Calvisi, Diego F
Chen, Xin https://orcid.org/0000-0002-9588-0164
Clinical trials referenced in this document:
Documents that mention this clinical trial
Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma
https://doi.org/10.1136/gutjnl-2020-320716
Documents that mention this clinical trial
Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma
https://doi.org/10.1136/gutjnl-2020-320716
1215 Spatial profiling identifies antigen-presenting CAFs as potential mediators of response to neoadjuvant immunotherapy in hepatocellular carcinoma
https://doi.org/10.1136/jitc-2025-sitc2025.1215
Integrated immunological analysis of a successful conversion of locally advanced hepatocellular carcinoma to resectability with neoadjuvant therapy
https://doi.org/10.1136/jitc-2020-000932
641 A pilot study of a DNAJB1-PRKACA fusion kinase peptide vaccine combined with nivolumab and ipilimumab for patients with fibrolamellar hepatocellular carcinoma
https://doi.org/10.1136/jitc-2023-sitc2023.0641
Immunotherapy for hepatocellular carcinoma: current status and future perspectives
https://doi.org/10.1136/esmoopen-2018-000455
Documents that mention this clinical trial
Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma
https://doi.org/10.1136/gutjnl-2020-320716
Funding for this research was provided by:
National Institutes of Health (R01CA239251)
National Institutes of Health (R03CA249236)
UCSF Liver Center (P30DK026743)